Clinically relevant preservation conditions for mesenchymal stem/stromal cells derived from perinatal and adult tissue sources

Spinal cord injury (SCI) is a devasting condition with no reliable treatment. Spina bifida is the most common cause of congenital SCI. Cell-based therapies using mesenchymal stem/stromal cells (MSCS) have been largely utilized in SCI. Several clinical trials for acquired SCI use adult tissue-derived MSC sources, including bone-marrow, adipose, and umbilical cord tissues. The first stem/stromal cell clinical trial for spina bifida is currently underway (NCT04652908). The trial uses early gestational placental-derived mesenchymal stem/stromal cells (PMSCs) during the fetal repair of myelomeningocele. PMSCs have been shown to exhibit unique neuroprotective, angiogenic, and antioxidant properties, all which are promising applications for SCI. This review will summarize the unique properties and current applications of PMSCs and discuss their therapeutic role for acquired SCI.

Download Full-text

Standardized xeno- and serum-free culture platform enables large-scale expansion of high-quality mesenchymal stem/stromal cells from perinatal and adult tissue sources

Cytotherapy ◽

10.1016/j.jcyt.2020.09.004 ◽

2021 ◽

Vol 23 (1) ◽

pp. 88-99

Author(s):

Van T. Hoang ◽

Quynh-Mai Trinh ◽

Dam Thi Minh Phuong ◽

Hue Thi Hong Bui ◽

Le Minh Hang ◽

...

Keyword(s):

Stromal Cells ◽

Large Scale ◽

Adult Tissue ◽

High Quality ◽

Serum Free ◽

Scale Expansion

Download Full-text

The therapeutic applications of mesenchymal stromal cells from human perinatal tissues in autoimmune diseases

Stem Cell Research & Therapy ◽

10.1186/s13287-021-02158-3 ◽

2021 ◽

Vol 12 (1) ◽

Author(s):

Chao Yang ◽

Mingjun Wu ◽

Min You ◽

Yu Chen ◽

Maowen Luo ◽

...

Keyword(s):

Autoimmune Diseases ◽

Stromal Cells ◽

Therapeutic Strategy ◽

Animal Experiments ◽

Therapeutic Strategies ◽

Adult Tissue ◽

Multiple Organs ◽

Cell Source ◽

Current Therapies ◽

The Ideal

AbstractThe autoimmune diseases are characterized by overactivation of immune cells, chronic inflammation, and immune response to self-antigens, leading to the damage and dysfunction of multiple organs. Patients still do not receive desired clinical outcomes while suffer from various adverse effects imparted by current therapies. The therapeutic strategies based on mesenchymal stromal cell (MSC) transplantation have become the promising approach for the treatment of autoimmune diseases due to the immunomodulation property of MSCs. MSCs derived from perinatal tissues are collectively known as perinatal MSCs (PMSCs), which can be obtained via painless procedures from donors with lower risk of being contaminated by viruses than those MSCs from adult tissue sources. Therefore, PMSCs may be the ideal cell source for the treatment of autoimmune diseases. This article summarizes recent progress and possible mechanisms of PMSCs in treating autoimmune diseases in animal experiments and clinical studies. This review also presents existing challenges and proposes solutions, which may provide new hints on PMSC transplantation as a therapeutic strategy for the treatment of autoimmune diseases.

Download Full-text